

Ref: EPL/CS/SE/0064/2025

Date: August 07, 2025

To,

National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051	BSE Limited P J Towers, Dalal Street, Mumbai- 400 001
Script Symbol: EMCURE	Scrp Code/Symbol: 544210/ EMCURE

Dear Sir/Madam,

Subject: Outcome of Board Meeting held on August 07, 2025.

In continuation to our letter dated July 28, 2025, and pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), we wish to inform that the Board of Directors of the Company at its meeting held today i.e. Thursday, August 07, 2025, has *inter-alia* approved the Unaudited Financial Results (Consolidated and Standalone) for the quarter ended June 30, 2025, as reviewed and recommended by the Audit Committee.

Pursuant to Regulation 33 of the SEBI Listing Regulations, we are enclosing herewith the Unaudited Financial Results (Consolidated and Standalone) for the quarter ended June 30, 2025, along with the Limited Review Reports on the aforesaid Results as issued by M/s. B S R & Co. LLP, Chartered Accountants, Auditors of the Company, enclosed as **Annexure A**.


Press Release outlining key updates on the Unaudited Financial Results (Consolidated and Standalone) for the quarter ended June 30, 2025, is also enclosed herewith as **Annexure B**.

The meeting of the Board of Directors of the Company commenced at 11.45 a.m. (IST) and concluded at 1.20 p.m. (IST).

You are requested to take the above information on your records.

Thanking you,

For Emcure Pharmaceuticals Limited



Chetan Sharma

Company Secretary & Compliance Officer

Membership Number: F8352



Encl: As above

Emcure Pharmaceuticals Limited**Registered Office:** Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India**Phone Nos.:** +91 20 - 35070033/ 35070000 **Fax No.:** +91 20 3507 0060**E-mail:** corporate@emcure.com **Website:** www.emcure.com **CIN:** L24231PN1981PLC024251

Annexure - A

B S R & Co. LLP

Chartered Accountants

8th floor, Business Plaza
Westin Hotel Campus
36/3-B, Koregaon Park Annex
Mundhwa Road, Ghorpadi
Pune - 411 001, India
Telephone: +91 (20) 6747 7300
Fax: +91 (20) 6747 7100

Limited Review Report on unaudited consolidated financial results of Emcure Pharmaceuticals Limited for the quarter ended 30 June 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Emcure Pharmaceuticals Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Emcure Pharmaceuticals Limited (hereinafter referred to as "the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 30 June 2025 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the entities mentioned in Annexure I to the Statement.
5. Attention is drawn to the fact that the figures for the three months ended 31 March 2025 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
6. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
7. The Statement includes the interim financial information of 17 Subsidiaries which have not been reviewed, whose interim financial information reflects total revenues (before consolidation adjustments) of Rs. 1,833 million, total net profit after tax (net) (before consolidation adjustments) of Rs. 108 million and total comprehensive income (net) (before consolidation adjustments) of Rs. 183 million, for the quarter ended 30 June 2025, as considered in the Statement. According to the information and explanations given to us by the Parent's management, these interim financial information are not material to the Group.

Registered Office:

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400063

Page 1 of 4



B S R & Co. LLP

Limited Review Report (Continued)

Emcure Pharmaceuticals Limited

Our conclusion is not modified in respect of this matter.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022



Abhishek

Partner

Pune

07 August 2025

Membership No.: 062343

UDIN: 250623438M0JCS4848

Limited Review Report (Continued)
Emcure Pharmaceuticals Limited

Annexure I

List of entities included in unaudited consolidated financial results:

Sr. No	Name of component	Relationship
1	Emcure Pharmaceuticals Limited ("EPL")	Parent/ Holding Company
2	Zuventus Healthcare Limited	Subsidiary of EPL
3	Gennova Biopharmaceuticals Limited	Subsidiary of EPL
4	Emcure Pharmaceuticals Pty Ltd	Subsidiary of EPL
5	Emcure Nigeria Limited	Subsidiary of EPL
6	Emcure Pharmaceuticals Mena FZ LLC	Subsidiary of EPL
7	Emcure Pharmaceuticals South Africa (Pty) Limited	Subsidiary of EPL
8	Emcure Brasil Farmaceutica Ltda	Subsidiary of EPL
9	Emcure Pharma UK Ltd ("EPUK")	Subsidiary of EPL
10	Emcure Pharma Peru S.A.C.	Subsidiary of EPL
11	Emcure Pharma Mexico S.A. DE C.V.	Subsidiary of EPL
12	Marcan Pharmaceuticals Inc. ("MPI")	Subsidiary of EPL
13	Emcure Pharma Chile SpA	Subsidiary of EPL
14	Lazor Pharmaceuticals Limited	Subsidiary of EPL
15	Emcure Pharma Philippines Inc.	Subsidiary of EPL
16	Emcure Pharmaceuticals Dominicana S.A.S	Subsidiary of EPL
17	Emcutix Biopharmaceuticals Limited	Subsidiary of EPL
18	Emcure Lifesciences Private Limited	Subsidiary of EPL
19	Tillomed Laboratories Ltd	Subsidiary of EPUK
20	Tillomed Pharma GmbH	Subsidiary of EPUK



Limited Review Report (Continued)
Emcure Pharmaceuticals Limited

21	Laboratories Tillomed Spain SLU	Subsidiary of EPUK
22	Tillomed Italia S.R.L.	Subsidiary of EPUK
23	Tillomed France SAS	Subsidiary of EPUK
24	Tillomed Malta Ltd.	Subsidiary of EPUK
25	Mantra Pharma Inc.	Subsidiary of MPI



Emcure Pharmaceuticals Limited				
Statement of Unaudited Consolidated Financial Results for the quarter ended June 30, 2025				
₹ in million (unless otherwise stated)				
Particulars	Quarter ended			Year ended
	30-Jun-25	31-Mar-25	30-Jun-24	31-Mar-25
	Unaudited	Refer note 6	Unaudited	Audited
Income:				
Revenue from operations	21,005.37	21,162.45	18,151.38	78,959.97
Other income (Refer note 5)	36.96	44.53	230.83	672.61
Total income	21,042.33	21,206.98	18,382.21	79,632.58
Expenses:				
Cost of materials consumed	4,325.02	4,038.73	3,317.17	15,269.01
Purchases of stock-in-trade	5,504.83	5,718.56	3,801.46	18,832.35
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,809.71)	(836.19)	(287.64)	(2,635.33)
Employee benefit expenses	3,934.71	3,733.65	3,504.01	14,462.92
Depreciation and amortisation expense	994.56	968.37	935.89	3,841.28
Finance costs	267.55	390.25	587.60	1,757.84
Other expenses	5,011.62	4,608.46	4,453.23	18,342.48
Net (gain) / loss on foreign currency transactions (Refer note 5)	(128.83)	(124.76)	(3.58)	(55.24)
Total expenses	18,099.75	18,497.07	16,308.14	69,815.31
Profit before exceptional items and tax	2,942.58	2,709.91	2,074.07	9,817.27
Exceptional items (refer note 3)	35.00	103.78	-	103.78
Profit before tax	2,907.58	2,606.13	2,074.07	9,713.49
Tax expense				
Current tax	860.18	915.53	618.70	2,921.57
Deferred tax	(100.53)	(281.77)	(70.53)	(282.75)
Total tax expenses	759.65	633.76	548.17	2,638.82
Profit for the period/year	2,147.93	1,972.37	1,525.90	7,074.67
Other comprehensive income				
(a) Other comprehensive income/(loss) not to be reclassified to profit or loss	(7.73)	(29.01)	(3.00)	(36.17)
- Income tax on above	2.05	7.73	0.76	9.74
(b) Other comprehensive income/(loss) to be reclassified to profit or loss	801.42	305.53	(13.74)	341.35
- Income tax on above	-	-	-	-
Other comprehensive income/(loss) for the period/year	795.74	284.25	(15.98)	314.92
Total comprehensive income for the period/year	2,943.67	2,256.62	1,509.92	7,389.59
Profit attributable to:				
Owners of the Holding company	2,069.53	1,889.57	1,440.81	6,813.32
Non-controlling interests	78.40	82.80	85.09	261.35
Other comprehensive income attributable to:				
Owners of the Holding company	796.35	286.60	(15.98)	317.41
Non-controlling interests	(0.61)	(2.35)	-	(2.49)
Total comprehensive income attributable to:				
Owners of the Holding company	2,865.88	2,176.17	1,424.83	7,130.73
Non-controlling interests	77.79	80.45	85.09	258.86
Earnings per share (not annualised for the Quarter ended):				
Basic	10.92	9.97	7.95	36.43
Diluted	10.92	9.97	7.95	36.43
Paid up equity share capital [Face value per share: Rs.10]	1,895.08	1,894.83	1,811.52	1,894.83
Other equity				42,567.03



Emcure Pharmaceuticals Limited

Building A-202, Ganga Osian Square, Wakad, Pune - 411 057, Maharashtra, India.

Phone : +91 20 - 35040000 / 66770000

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

Phone Nos.: +91 20 - 35070033/ 35070000 Fax No.: +91 20 3507 0060

E-mail: corporate@emcure.com Website: www.emcure.com CIN: L24231PN1981PLC024251

Emcure Pharmaceuticals Limited
Statement of Unaudited Consolidated Financial Results for the quarter ended June 30, 2025

Notes:

1. These unaudited consolidated financial results of the Holding Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 ("the Regulations"). The said unaudited consolidated financial results represent the results of Emcure Pharmaceutical Limited ("Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") for the quarter ended June 30, 2025.
2. The above unaudited consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Holding Company at their respective meetings held on August 7, 2025. The results are subjected to Limited Review by the statutory auditors of the Holding Company in terms of Regulation 33 of The Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (LODR), as amended. The statutory auditors have expressed an unqualified conclusion on above unaudited consolidated financial results.
3. Exceptional item for the quarter ended June 30, 2025, includes Rs. 35.00 million for a one-time settlement agreement of a legal dispute entered during the current quarter. Further, amount disclosed under the quarter and year ended March 31, 2025 pertains to consultancy fees paid in relation to Canada Drug Pricing Matter and amount paid towards legal settlements.
4. The Group is primarily engaged in manufacturing and trading of pharmaceuticals products. Accordingly, the Group has only one reportable segment 'Pharmaceuticals' and disclosures as per Ind AS 108 "Operating Segments" are not applicable.
5. The Group has elected to present gains or losses arising from foreign exchange differences as a separate line item on the face of the statement of profit and loss. Accordingly the figures for previous periods have been reclassified as below:

Particulars	₹ in million		
	Quarter ended 30-Jun-24		
	Reported	Reclassification	Revised
Other income	234.41	(3.58)	230.83
Other Expenses : Net (gain) / loss on foreign currency transactions	-	(3.58)	(3.58)

6. The figures for the quarter ended March 31, 2025 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published year to date figures up to the third quarter of the relevant financial year which were subject to limited review by the Statutory Auditor of the Holding Company.
7. Tillomed Laboratories Limited ("Tillomed"), a stepdown subsidiary of the Holding Company, entered into an Asset Purchase Agreement (APA) with UK based Manx Healthcare Limited and its subsidiaries (collectively Manx). Under the APA, Tillomed acquired Manx's product portfolio inclusive of relevant Dossiers, Marketing Authorisations, Intellectual Property (collectively Intellectual Properties) and the relevant stocks for around £ 19.68 million [Rs. 2,202.49 million] (including £ 4.68 million [Rs. 523.76 million] for inventory). Pursuant to said APA agreement, inventory amounting to £ 3.95 million (Rs. 442.52 million) has been purchased from Manx during the quarter ended June 30, 2025.
8. The Holding Company's Board of Directors approved acquisition of shares from the minority shareholders of Zuventus Healthcare Ltd ('Zuventus'), one of its subsidiaries. Once the transaction is completed Zuventus will become a wholly owned subsidiary of Emcure. The transaction is expected to be completed by September 2025.

For and on behalf of the Board of Directors

Emcure Pharmaceuticals Limited

CIN: L24231PN1981PLC024251

Satish Menta

Managing Director & CEO

DIN: 00118691

Place: Pune

Date: 7 August 2025



B S R & Co. LLP

Chartered Accountants

8th floor, Business Plaza
Westin Hotel Campus
36/3-B, Koregaon Park Annex
Mundhwa Road, Ghorpadi
Pune - 411 001, India
Telephone: +91 (20) 6747 7300
Fax: +91 (20) 6747 7100

Limited Review Report on unaudited standalone financial results of Emcure Pharmaceuticals Limited for the quarter ended 30 June 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Emcure Pharmaceuticals Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Emcure Pharmaceuticals Limited (hereinafter referred to as "the Company") for the quarter ended 30 June 2025 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Attention is drawn to the fact that the figures for the three months ended 31 March 2025 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it



B S R & Co. LLP

Limited Review Report (Continued)
Emcure Pharmaceuticals Limited

contains any material misstatement.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.: 101248W/W-100022



Abhishek

Partner

Pune

07 August 2025

Membership No.: 062343

UDIN: 25062343BM0JCR1302

Emcure Pharmaceuticals Limited				
Statement of Unaudited Standalone Financial Results for the quarter ended June 30, 2025				
₹ in million (unless otherwise stated)				
Particulars	Quarter ended			Year Ended
	30-Jun-25	31-Mar-25	30-Jun-24	31-Mar-25
	Unaudited	Refer note 6	Unaudited	Audited
Income:				
Revenue from operations	10,965.73	12,781.88	9,702.93	43,819.24
Other income (Refer note 5)	215.24	223.96	279.43	1,188.07
Total income	11,180.97	13,005.84	9,982.36	45,007.31
Expenses:				
Cost of materials consumed	3,546.28	3,650.12	2,660.68	13,079.75
Purchases of stock-in-trade	1,601.75	2,598.29	1,584.55	8,257.02
Changes in inventories of finished goods, work-in-progress and stock in trade	(1,066.18)	(168.59)	(84.16)	(1,262.65)
Employee benefit expenses	2,104.19	1,981.60	1,950.89	7,823.10
Depreciation and amortisation expense	598.17	569.12	550.79	2,249.72
Finance cost	205.38	240.69	375.67	1,129.62
Other expenses	2,566.90	2,335.29	2,439.09	9,690.36
Net (gain)/ loss on foreign currency transactions (Refer note 5)	(67.21)	(61.20)	(45.63)	(236.71)
Total expenses	9,489.28	11,145.32	9,431.88	40,730.21
Profit before exceptional items and tax	1,691.69	1,860.52	550.48	4,277.10
Exceptional items (refer note 3)	35.00	-	-	-
Profit before tax	1,656.69	1,860.52	550.48	4,277.10
Tax expense				
Current tax	440.03	635.90	129.13	1,127.07
Deferred tax	(11.23)	(170.95)	16.89	(21.25)
Total tax expenses	428.80	464.95	146.02	1,105.82
Profit for the Period/Year	1,227.89	1,395.57	404.46	3,171.28
Other comprehensive income				
Other comprehensive income/(loss) not to be reclassified to profit or loss in subsequent period	(3.00)	(10.71)	(3.00)	(16.21)
- Income tax on above	0.76	2.70	0.76	4.08
Other comprehensive income/(loss) for the period/year	(2.24)	(8.01)	(2.24)	(12.13)
Total comprehensive income for the period/year	1,225.65	1,387.56	402.22	3,159.15
Earnings per share (not annualised for the Quarters)				
Basic	6.48	7.37	2.23	16.95
Diluted	6.48	7.37	2.23	16.95
Paid-up equity share capital (Face value per share : Rs.10)	1,895.08	1,894.83	1,811.52	1,894.83
Other equity				28,348.81



Emcure Pharmaceuticals Limited

Building A-202, Ganga Osian Square, Wakad, Pune - 411 057, Maharashtra, India.

Phone : +91 20 - 35040000 / 66770000

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

Phone Nos.: +91 20 – 35070033/ 35070000 **Fax No.:** +91 20 3507 0060

E-mail: corporate@emcure.com **Website:** www.emcure.com **CIN:** L24231PN1981PLC024251

Emcure Pharmaceuticals Limited
Statement of Unaudited Standalone Financial Results for the quarter ended June 30, 2025

Notes:

1. These unaudited standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 ("the Regulations").
2. The above unaudited standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on August 7, 2025. The results are subjected to limited review by the statutory auditors of the Company in terms of Regulation 33 of The Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (LODR), as amended. The statutory auditors have expressed an unqualified conclusion on above unaudited standalone financial results.
3. Exceptional item for the quarter ended June 30, 2025, includes Rs. 35.00 million for a one-time settlement agreement of a legal dispute entered during the current quarter.
4. In accordance with Ind AS 108 "Operating Segments", segment information has been provided in the consolidated financial results of the Group and therefore no separate disclosure on segment information is given in these standalone financial results.
5. The Company has elected to present gains or losses arising from foreign exchange differences as a separate line item on the face of the statement of profit and loss. Accordingly the figures for previous periods which were earlier reported have been reclassified as below:

Particulars	₹ in million		
	Quarter ended 30-June-24		
	Reported	Reclassification	Revised
Other income	325.06	(45.63)	279.43
Other Expenses - Net (gain) / loss on foreign currency transactions	-	(45.63)	(45.63)

6. The figures for the quarter ended March 31, 2025 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published year to date figures up to the third quarter of the relevant financial year which were subject to limited review by the Statutory Auditor of the Company.
7. The Company's Board of Directors approved acquisition of shares from the minority shareholders of Zuventus Healthcare Ltd ('Zuventus'), one of its subsidiaries. Once the transaction is completed Zuventus will become a wholly owned subsidiary of Emcure. The transaction is expected to be completed by September 2025.

For and on behalf of the Board of Directors
Emcure Pharmaceuticals Limited
CIN: L24231PN1981PLC024251


Satish Mehta
Managing Director & CEO
DIN: 00118691

Place: Pune
Date: 07 August 2025



Emcure Pharmaceuticals Achieves Strong Q1FY26 Performance with 16% Revenue Growth and 41% Profit After Tax Growth

- Revenue from operations at Rs. 2,101Cr, up 15.7% YoY
- EBITDA margins at 19.2% with EBITDA up 20.1% YoY
- PAT at Rs. 215 Cr, up 41% YoY
- Domestic business sales at Rs. 995 Cr, up 9.4% YoY
- International business sales at Rs. 1,106 Cr, up 22.1% YoY

Pune, Aug 7, 2025: Emcure Pharmaceuticals (BSE: 544210, NSE: EMCURE) today announced its consolidated financial results for the quarter ended June 30th, 2025.

The quarter saw robust performance from both Domestic and International businesses. Emcure's International business grew 22% with all businesses performing. Rest of the World business continued the healthy momentum growing 42%. Company's Canada business grew 16.4% led by new launches and market share gains. Europe saw early benefits of new launches and grew 12.8%.

Domestic business grew 9.4% led by strong performance in all out key therapies and aided by new initiatives in Derma and OTC. During the quarter, the company further strengthened its domestic business through expansion of its strategic partnership with Sanofi. Going forward, Emcure will be marketing and distributing Sanofi's Oral Anti-diabetic portfolio in addition to the cardiovascular portfolio.

Commenting on the results, Satish Mehta, CEO and Managing Director, Emcure Pharmaceuticals Ltd., said, "We delivered robust performance across all businesses in Q1. We continue to augment our portfolio in all our focus markets through in-licensing and in-house development. The expanded Sanofi partnership positions us well in the fast growing metabolic segment. We also have a strong product pipeline for both our domestic and international markets which will fuel future growth. We remain focused on improving efficiencies to drive sustained improvement in margins. "

Revenue break-up:

Rs. Cr	1Q26	1Q25	YOY%	4Q25	QOQ%
Revenue from operations	2,101	1,815	15.7%	2,116	-0.7%
Domestic	995	909	9.4%	929	7.1%
International	1,106	906	22.1%	1,187	-6.9%
EM	360	254	41.9%	481	-25.1%
EU	403	358	12.8%	396	1.9%
CA	342	294	16.4%	310	10.1%

Contd.

Performance Summary (Consolidated)

Rs. Cr	1Q26	1Q25	YOY%	4Q25	QOQ%
Revenue from operations	2,101	1,815	15.72%	2,116	-0.74%
Material Cost	802	683	17.41%	892	-10.10%
Gross Profit	1,299	1,132	14.71%	1,224	6.08%
<i>Gross Profit Margins</i>	<i>61.8%</i>	<i>62.4%</i>		<i>57.8%</i>	
Employee Costs	393	350	12.29%	373	5.39%
Other expenses	501	445	12.54%	461	8.75%
EBITDA	404	336	20.09%	390	3.58%
<i>EBITDA Margins</i>	<i>19.23%</i>	<i>18.53%</i>		<i>18.43%</i>	
Other Income	4	23		4	
Depreciation and Amortisation	99	94		97	
Finance Costs inc. Forex	14	59		26	
Exceptional Items	4	0		10	
Profit Before Tax (PBT)	291	207	40.19%	261	11.57%
Tax	76	55		63	
Profit After Tax (PAT)	215	153	40.76%	197	8.90%
<i>PAT Margins</i>	<i>10.2%</i>	<i>8.4%</i>		<i>9.3%</i>	

About Emcure Pharmaceuticals Ltd:

Emcure Pharmaceuticals Ltd. (EPL) is a leading Indian pharma company headquartered in Pune engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products. Known for its commitment to innovation, quality, and patient-centricity, Emcure is an R&D driven company that develops and manufactures a wide range of differentiated pharmaceutical products designed to improve patient health and well-being across several major therapeutic areas. Established in 1981, EPL is ranked as the 12th largest pharma company in India in terms of Domestic Sales for MAT June 2024. Emcure is present in 70+ countries globally including Europe and Canada.

Contact:

Media

corpcomm@emcure.com

Investor Relations

investor.relations@emcure.com

Details of the Earnings Call:

- **Date:** Thursday, Aug 07, 2025
- **Time:** 3:30 p.m. – 4:30 p.m. (IST)
- **Dial-In Numbers:**
 - Universal Access: [+91 22 6280 1220](tel:+912262801220) / [+91 22 7115 8122](tel:+912271158122)
 - USA: 1 866 746 2133
 - UK: 0 808 101 1573
 - Singapore: 800 101 2045
 - Hong Kong: 800 964 448